Eliem Therapeutics IncNASDAQ:ELYM
- LAST PRICE3.9200
- TODAY'S CHANGE (%)0.5300 (15.6342%)
- Bid / Lots3.7000/ 20
- Ask / Lots3.9300/ 1
- Open / Previous Close3.4900 / 3.3900
- Day Range
- 52 Week Range
- Volume335,039
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ELYM |
|---|---|---|
| 09:32 ET | 1978 | 3.51 |
| 09:34 ET | 400 | 3.545 |
| 09:36 ET | 162 | 3.545 |
| 09:39 ET | 100 | 3.545 |
| 09:45 ET | 9438 | 3.5475 |
| 09:52 ET | 400 | 3.47 |
| 09:56 ET | 1077 | 3.4937 |
| 09:57 ET | 126 | 3.55 |
| 09:59 ET | 100 | 3.5 |
| 10:15 ET | 400 | 3.46 |
| 10:17 ET | 300 | 3.33 |
| 10:19 ET | 754 | 3.34 |
| 10:21 ET | 1500 | 3.38 |
| 10:24 ET | 2344 | 3.36 |
| 10:26 ET | 800 | 3.39 |
| 10:28 ET | 1700 | 3.39 |
| 10:30 ET | 2190 | 3.38 |
| 10:32 ET | 900 | 3.335 |
| 10:33 ET | 2806 | 3.38 |
| 10:35 ET | 3317 | 3.37 |
| 10:37 ET | 1506 | 3.4499 |
| 10:39 ET | 10300 | 3.5 |
| 10:44 ET | 27550 | 3.42 |
| 10:46 ET | 5000 | 3.5 |
| 10:48 ET | 9700 | 3.44 |
| 10:50 ET | 5076 | 3.49 |
| 10:51 ET | 3408 | 3.52 |
| 11:00 ET | 29800 | 3.565 |
| 11:09 ET | 1000 | 3.54 |
| 11:11 ET | 4700 | 3.6 |
| 11:13 ET | 200 | 3.63 |
| 11:15 ET | 200 | 3.625 |
| 11:18 ET | 1100 | 3.6 |
| 11:20 ET | 1285 | 3.62 |
| 11:24 ET | 300 | 3.7 |
| 11:26 ET | 321 | 3.7 |
| 11:27 ET | 600 | 3.7 |
| 11:29 ET | 1398 | 3.7 |
| 11:33 ET | 100 | 3.8 |
| 11:40 ET | 2321 | 3.7501 |
| 11:42 ET | 4090 | 3.85 |
| 11:44 ET | 22534 | 3.9 |
| 11:45 ET | 31035 | 4.1 |
| 11:47 ET | 11325 | 3.92 |
| 11:56 ET | 10538 | 3.74 |
| 11:58 ET | 8162 | 3.825 |
| 12:00 ET | 600 | 3.85 |
| 12:02 ET | 100 | 3.85 |
| 12:09 ET | 1148 | 3.9 |
| 12:12 ET | 2600 | 3.85 |
| 12:16 ET | 480 | 3.9 |
| 12:20 ET | 200 | 3.85 |
| 12:21 ET | 269 | 3.721 |
| 12:25 ET | 200 | 3.825 |
| 12:34 ET | 100 | 3.825 |
| 12:38 ET | 100 | 3.825 |
| 12:41 ET | 100 | 3.825 |
| 12:45 ET | 100 | 3.825 |
| 12:50 ET | 100 | 3.825 |
| 12:54 ET | 900 | 3.825 |
| 12:56 ET | 300 | 3.8999 |
| 12:57 ET | 100 | 3.8525 |
| 12:59 ET | 32102 | 3.89 |
| 01:01 ET | 2452 | 3.89 |
| 01:03 ET | 3900 | 3.89 |
| 01:12 ET | 100 | 3.855 |
| 01:14 ET | 7496 | 3.9 |
| 01:15 ET | 8698 | 3.895 |
| 01:17 ET | 17900 | 3.89 |
| 01:19 ET | 18438 | 3.9 |
| 01:21 ET | 4555 | 3.92 |
Yesterday
Apr 22, 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INRD, AIRC, ELYM, ALPN, from 11:12AM ET on Monday Apr 22, 2024 by Dow Jones
11:12AM ET on Monday Apr 22, 2024 by Dow JonesKuehn Law Encourages INRD, AIRC, ELYM, and ALPN Investors to Contact Law Firm, from 9:48AM ET on Monday Apr 22, 2024 by Dow Jones
9:48AM ET on Monday Apr 22, 2024 by Dow Jones
Apr 15, 2024
Apr 13, 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, ALPN, ELYM, JBT, from 9:29AM ET on Saturday Apr 13, 2024 by Dow Jones
9:29AM ET on Saturday Apr 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Eliem Therapeutics Inc | 95.1M | -3.0x | --- |
IO Biotech Inc | 95.5M | -0.7x | --- |
DiaMedica Therapeutics Inc | 96.0M | -4.1x | --- |
Anixa Biosciences Inc | 95.1M | -9.2x | --- |
Elicio Therapeutics Inc | 93.1M | -1.0x | --- |
Vigil Neuroscience Inc | 97.0M | -1.2x | --- |
Company Information
Eliem Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. Its clinical-stage program, ETX-155, is an investigational, oral, neuroactive steroid NCE that is designed to act as a positive allosteric modulator (PAM) of the GABAA receptor (GABAAR). The GABAA PAM neuroactive steroid class has been clinically validated in depression and epilepsy, with Sage Therapeutics receiving approval from the United States. ETX-155 for use in multiple disorders of high unmet need, including major depressive disorder (MDD) and focal onset seizures (FOS). It has designed several lead series based on novel chemistry and selected a lead clinical candidate, ETX-123. The ETX-123 molecule displays potent activation of Kv7.2/3 in vitro with an approximately 0.7 nM EC50.
Contact Information
- Headquarters
- 2801 CENTERVILLE ROAD 1ST FLOOR PMB #117WILMINGTON, DE, United States 19808
- Phone
- 425-276-2300
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board, Interim Principal Executive Officer
- Andrew Levin
- Executive Vice President - Research and Development, Chief Scientific Officer
- Valerie Morisset
- Chief Accounting Officer
- Emily Pimblett
- Lead Independent Director
- Liam Ratcliffe
- Independent Director
- Judith Dunn
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $95.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 28.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.31 |
Book Value | $3.88 |
P/E Ratio | -3.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
